For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
The second half of 2019 saw half as many innovative medical devices approved as the first.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.